Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCT to Provide Update on CD47 Program at the 2014 AACR Annual Meeting

Published: Friday, April 04, 2014
Last Updated: Friday, April 04, 2014
Bookmark and Share
Announcing a key difference between SIRPaFc and other CD47-blocking agents.

Stem Cell Therapeutics Corp. has announced that it will be providing an update on its SIRPaFc immune checkpoint inhibitor program, targeting the CD47 protein, at the 105th Annual Meeting of the American Association for Cancer Research.

The meeting will be held April 5-9, 2014 in San Diego, CA. Details of the poster presentation, entitled “Cancer Immunotherapy Targeting CD47: Wild Type SIRPaFc is the Ideal CD47-Blocking Agent to Minimize Unwanted Erythrocyte Binding”, are listed below:

Date: Wednesday April 9, 2014
Time: 8:00 am - 12:00 pm (PT)
Session ID: Immunology 11
Session Title: Immune Checkpoint Inhibition
Abstract #: 5011
Presenter: Dr. Robert Uger, Chief Scientific Officer
Location: Hall A-E, Poster Section 10, San Diego Convention Center

The company will present data demonstrating that its wild type SIRPaFc fusion protein, which binds effectively to CD47 with low nanomolar affinity, binds very poorly to human red blood cells (RBCs) compared to both commercial anti-CD47 monoclonal antibodies (mAbs) and proprietary CD47-blocking agents.

This striking difference in binding was not seen with other cell types, including acute myeloid leukemia (AML) tumor cells, suggesting it is an RBC-specific phenomenon. In addition, the lack of significant SIRPaFc binding to erythrocytes is unique to humans, since SIRPaFc bound strongly to mouse and non-human primate RBCs.

Overall, the data suggest that a wild type SIRPaFc fusion protein may be the ideal CD47-blocking agent to reduce the potential antigen sink effect caused by RBCs and to minimize hematological toxicity in patients, while maintaining potent anti-tumor effects.

“Our results are consistent with independently published reports documenting differences in binding between CD47-specific antibodies and the natural CD47 ligand, SIRPa. While the mechanism behind this observation is still under investigation, our preliminary data suggest that it may relate to unique structural features of CD47 in the human RBC membrane,” commented Dr. Uger.

Dr. Uger continued, “Importantly, our results indicate that our SIRPaFc protein has a preferable RBC binding profile compared to competing approaches, which we believe may predict a lower risk of toxicity in patients and a more favorable pharmacokinetic profile.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCT Changes its Name to Trillium Therapeutics Inc.
Company has filed articles of amalgamation to merge with Trillium Therapeutics.
Tuesday, June 03, 2014
Stem Cell Therapeutics Completes $33 Million Private Placement
Financing proceeds used to advance the Company’s CD47 cancer stem cell program.
Friday, December 20, 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation
Company receives drug designation for the use of tigecycline to treat AML.
Friday, November 01, 2013
SCT Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
SCT Licenses Exclusive Rights to Clinical Cancer Stem Cell Program
Corporate refocusing mission completed.
Friday, April 19, 2013
SCT Announces Agreement with Trillium for Merger
Continuing Stem Cell Therapeutics' commitment to expansion.
Wednesday, February 06, 2013
Stem Cell Therapeutics Announces Agreement with UHN and MaRS Innovation
Building on the continued strength of Canadian stem cell research.
Thursday, November 08, 2012
Scientific News
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!